269 related articles for article (PubMed ID: 30328750)
41. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.
Hatlen MA; Wang L; Nimer SD
Front Med; 2012 Sep; 6(3):248-62. PubMed ID: 22875638
[TBL] [Abstract][Full Text] [Related]
42. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J
Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333
[TBL] [Abstract][Full Text] [Related]
43. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
[TBL] [Abstract][Full Text] [Related]
44. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
[TBL] [Abstract][Full Text] [Related]
45. UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8.
Fukuyama T; Kitamura T; Kozu T
Int J Hematol; 2022 May; 115(5):686-693. PubMed ID: 35152350
[TBL] [Abstract][Full Text] [Related]
46. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
[TBL] [Abstract][Full Text] [Related]
47. The RUNX1/RUNX1T1 network: translating insights into therapeutic options.
Swart LE; Heidenreich O
Exp Hematol; 2021 Feb; 94():1-10. PubMed ID: 33217477
[TBL] [Abstract][Full Text] [Related]
48. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
Martens JH; Mandoli A; Simmer F; Wierenga BJ; Saeed S; Singh AA; Altucci L; Vellenga E; Stunnenberg HG
Blood; 2012 Nov; 120(19):4038-48. PubMed ID: 22983443
[TBL] [Abstract][Full Text] [Related]
49. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia.
Kuchenbauer F; Feuring-Buske M; Buske C
Cell Cycle; 2005 Dec; 4(12):1716-8. PubMed ID: 16294039
[TBL] [Abstract][Full Text] [Related]
50. [Effect of AML1-ETO fusion protein on the expression of BCL-2].
Zhuang WY; Li ZY; Zhao Y; Cen JN; Zhuang WZ; Chen ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1394-8. PubMed ID: 24370018
[TBL] [Abstract][Full Text] [Related]
51. Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
Chen D; Chen W
Br J Haematol; 2021 May; 193(4):691. PubMed ID: 33386742
[No Abstract] [Full Text] [Related]
52. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition.
Rulina AV; Spirin PV; Prassolov VS
Biochemistry (Mosc); 2010 Dec; 75(13):1650-66. PubMed ID: 21417999
[TBL] [Abstract][Full Text] [Related]
53. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
[TBL] [Abstract][Full Text] [Related]
54.
Wang Y; Liu Y; Xu Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613512
[TBL] [Abstract][Full Text] [Related]
55. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
[TBL] [Abstract][Full Text] [Related]
56. CD7+ near-tetraploid acute myeloblastic leukemia M2 with double t(8;21)(q22;q22) translocations and Aml1/ETO rearrangements detected by fluorescence in situ hybridization analysis.
Yamamoto K; Nagata K; Kida A; Tsurukubo Y; Hamaguchi H
Int J Hematol; 2001 Oct; 74(3):316-21. PubMed ID: 11721969
[TBL] [Abstract][Full Text] [Related]
57. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
[TBL] [Abstract][Full Text] [Related]
58. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
[TBL] [Abstract][Full Text] [Related]
59. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
[TBL] [Abstract][Full Text] [Related]
60. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]